Oncologic Efficacy of Laparoscopic RPLND in Treatment of Clinical Stage I Nonseminomatous Germ Cell Testicular Cancer

Matthew E. Nielsen, Guilherme Lima, Edward M. Schaeffer, James Porter, Jeffrey A. Cadeddu, Ingolf Tuerk, Louis R. Kavoussi

Research output: Contribution to journalArticle

Abstract

Objectives: To assess the oncologic efficacy of laparoscopic retroperitoneal lymph node dissection (LRPLND) for clinical Stage I nonseminomatous germ cell tumors (NSGCTs) in a large multi-institutional series. LRPLND is emerging as a less-invasive alternative in the adjuvant surgical treatment of patients with testicular cancer. Methods: The medical records of 120 patients with clinical Stage I NSGCT who underwent LRPLND at one of four institutions in the United States were retrospectively analyzed. All patients had at least 12 months of postoperative follow-up. The modified template dissection was performed at all centers. For the purposes of analysis, the patients were divided into two groups: those with consonant clinical and pathologic Stage I disease (n = 74, 62%) and those upstaged to pathologic Stage II (n = 46, 38%). Results: No patient, including those upstaged to pathologic Stage II disease undergoing surveillance (n = 10), presented with retroperitoneal recurrence after LRPLND. Two patients with consonant pathologic Stage I developed pelvic recurrence that was outside the standard dissection template. The median follow-up for the patients with pathologic Stage I was 28.5 months (range 12 to 144) and was 29 months (range 12 to 108) for those with pathologic Stage II. Conclusions: In this group of patients with clinical Stage I NSGCT, management at multiple institutions that included LRPLND provided excellent intermediate results, paralleling those historically achieved with open lymph node dissection.

Original languageEnglish (US)
Pages (from-to)1168-1172
Number of pages5
JournalUrology
Volume70
Issue number6
DOIs
StatePublished - Dec 2007

Fingerprint

Germ Cell and Embryonal Neoplasms
Testicular Neoplasms
Lymph Node Excision
Therapeutics
Dissection
Recurrence
Medical Records

ASJC Scopus subject areas

  • Urology

Cite this

Nielsen, M. E., Lima, G., Schaeffer, E. M., Porter, J., Cadeddu, J. A., Tuerk, I., & Kavoussi, L. R. (2007). Oncologic Efficacy of Laparoscopic RPLND in Treatment of Clinical Stage I Nonseminomatous Germ Cell Testicular Cancer. Urology, 70(6), 1168-1172. https://doi.org/10.1016/j.urology.2007.08.041

Oncologic Efficacy of Laparoscopic RPLND in Treatment of Clinical Stage I Nonseminomatous Germ Cell Testicular Cancer. / Nielsen, Matthew E.; Lima, Guilherme; Schaeffer, Edward M.; Porter, James; Cadeddu, Jeffrey A.; Tuerk, Ingolf; Kavoussi, Louis R.

In: Urology, Vol. 70, No. 6, 12.2007, p. 1168-1172.

Research output: Contribution to journalArticle

Nielsen, ME, Lima, G, Schaeffer, EM, Porter, J, Cadeddu, JA, Tuerk, I & Kavoussi, LR 2007, 'Oncologic Efficacy of Laparoscopic RPLND in Treatment of Clinical Stage I Nonseminomatous Germ Cell Testicular Cancer', Urology, vol. 70, no. 6, pp. 1168-1172. https://doi.org/10.1016/j.urology.2007.08.041
Nielsen, Matthew E. ; Lima, Guilherme ; Schaeffer, Edward M. ; Porter, James ; Cadeddu, Jeffrey A. ; Tuerk, Ingolf ; Kavoussi, Louis R. / Oncologic Efficacy of Laparoscopic RPLND in Treatment of Clinical Stage I Nonseminomatous Germ Cell Testicular Cancer. In: Urology. 2007 ; Vol. 70, No. 6. pp. 1168-1172.
@article{84d7d8bef6684ac6a892aa3da5f0d9f5,
title = "Oncologic Efficacy of Laparoscopic RPLND in Treatment of Clinical Stage I Nonseminomatous Germ Cell Testicular Cancer",
abstract = "Objectives: To assess the oncologic efficacy of laparoscopic retroperitoneal lymph node dissection (LRPLND) for clinical Stage I nonseminomatous germ cell tumors (NSGCTs) in a large multi-institutional series. LRPLND is emerging as a less-invasive alternative in the adjuvant surgical treatment of patients with testicular cancer. Methods: The medical records of 120 patients with clinical Stage I NSGCT who underwent LRPLND at one of four institutions in the United States were retrospectively analyzed. All patients had at least 12 months of postoperative follow-up. The modified template dissection was performed at all centers. For the purposes of analysis, the patients were divided into two groups: those with consonant clinical and pathologic Stage I disease (n = 74, 62{\%}) and those upstaged to pathologic Stage II (n = 46, 38{\%}). Results: No patient, including those upstaged to pathologic Stage II disease undergoing surveillance (n = 10), presented with retroperitoneal recurrence after LRPLND. Two patients with consonant pathologic Stage I developed pelvic recurrence that was outside the standard dissection template. The median follow-up for the patients with pathologic Stage I was 28.5 months (range 12 to 144) and was 29 months (range 12 to 108) for those with pathologic Stage II. Conclusions: In this group of patients with clinical Stage I NSGCT, management at multiple institutions that included LRPLND provided excellent intermediate results, paralleling those historically achieved with open lymph node dissection.",
author = "Nielsen, {Matthew E.} and Guilherme Lima and Schaeffer, {Edward M.} and James Porter and Cadeddu, {Jeffrey A.} and Ingolf Tuerk and Kavoussi, {Louis R.}",
year = "2007",
month = "12",
doi = "10.1016/j.urology.2007.08.041",
language = "English (US)",
volume = "70",
pages = "1168--1172",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Oncologic Efficacy of Laparoscopic RPLND in Treatment of Clinical Stage I Nonseminomatous Germ Cell Testicular Cancer

AU - Nielsen, Matthew E.

AU - Lima, Guilherme

AU - Schaeffer, Edward M.

AU - Porter, James

AU - Cadeddu, Jeffrey A.

AU - Tuerk, Ingolf

AU - Kavoussi, Louis R.

PY - 2007/12

Y1 - 2007/12

N2 - Objectives: To assess the oncologic efficacy of laparoscopic retroperitoneal lymph node dissection (LRPLND) for clinical Stage I nonseminomatous germ cell tumors (NSGCTs) in a large multi-institutional series. LRPLND is emerging as a less-invasive alternative in the adjuvant surgical treatment of patients with testicular cancer. Methods: The medical records of 120 patients with clinical Stage I NSGCT who underwent LRPLND at one of four institutions in the United States were retrospectively analyzed. All patients had at least 12 months of postoperative follow-up. The modified template dissection was performed at all centers. For the purposes of analysis, the patients were divided into two groups: those with consonant clinical and pathologic Stage I disease (n = 74, 62%) and those upstaged to pathologic Stage II (n = 46, 38%). Results: No patient, including those upstaged to pathologic Stage II disease undergoing surveillance (n = 10), presented with retroperitoneal recurrence after LRPLND. Two patients with consonant pathologic Stage I developed pelvic recurrence that was outside the standard dissection template. The median follow-up for the patients with pathologic Stage I was 28.5 months (range 12 to 144) and was 29 months (range 12 to 108) for those with pathologic Stage II. Conclusions: In this group of patients with clinical Stage I NSGCT, management at multiple institutions that included LRPLND provided excellent intermediate results, paralleling those historically achieved with open lymph node dissection.

AB - Objectives: To assess the oncologic efficacy of laparoscopic retroperitoneal lymph node dissection (LRPLND) for clinical Stage I nonseminomatous germ cell tumors (NSGCTs) in a large multi-institutional series. LRPLND is emerging as a less-invasive alternative in the adjuvant surgical treatment of patients with testicular cancer. Methods: The medical records of 120 patients with clinical Stage I NSGCT who underwent LRPLND at one of four institutions in the United States were retrospectively analyzed. All patients had at least 12 months of postoperative follow-up. The modified template dissection was performed at all centers. For the purposes of analysis, the patients were divided into two groups: those with consonant clinical and pathologic Stage I disease (n = 74, 62%) and those upstaged to pathologic Stage II (n = 46, 38%). Results: No patient, including those upstaged to pathologic Stage II disease undergoing surveillance (n = 10), presented with retroperitoneal recurrence after LRPLND. Two patients with consonant pathologic Stage I developed pelvic recurrence that was outside the standard dissection template. The median follow-up for the patients with pathologic Stage I was 28.5 months (range 12 to 144) and was 29 months (range 12 to 108) for those with pathologic Stage II. Conclusions: In this group of patients with clinical Stage I NSGCT, management at multiple institutions that included LRPLND provided excellent intermediate results, paralleling those historically achieved with open lymph node dissection.

UR - http://www.scopus.com/inward/record.url?scp=37349125538&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37349125538&partnerID=8YFLogxK

U2 - 10.1016/j.urology.2007.08.041

DO - 10.1016/j.urology.2007.08.041

M3 - Article

C2 - 18158040

AN - SCOPUS:37349125538

VL - 70

SP - 1168

EP - 1172

JO - Urology

JF - Urology

SN - 0090-4295

IS - 6

ER -